C
C. Robert Horsburgh
Researcher at Boston University
Publications - 209
Citations - 10473
C. Robert Horsburgh is an academic researcher from Boston University. The author has contributed to research in topics: Tuberculosis & Medicine. The author has an hindex of 48, co-authored 170 publications receiving 9027 citations. Previous affiliations of C. Robert Horsburgh include Centers for Disease Control and Prevention & San Francisco General Hospital.
Papers
More filters
Journal ArticleDOI
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling,M. Elsa Villarino,Andrey S. Borisov,Nong Shang,Fred M. Gordin,Erin Bliven-Sizemore,Judith Hackman,Carol Dukes Hamilton,Dick Menzies,Amy Kerrigan,Stephen E. Weis,Marc H Weiner,Diane Wing,Marcus Barreto Conde,Lorna Bozeman,C. Robert Horsburgh,Richard E. Chaisson +16 more
TL;DR: The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniaZid alone in preventing tuberculosis and had a higher treatment-completion rate.
Journal ArticleDOI
Priorities for the Treatment of Latent Tuberculosis Infection in the United States
TL;DR: Improved rates of completion of treatment among persons with specific medical conditions could help to eliminate tuberculosis in the United States.
Journal ArticleDOI
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Keertan Dheda,Tawanda Gumbo,Gary Maartens,Kelly E. Dooley,Ruth McNerney,Megan Murray,Jennifer Furin,Edward A. Nardell,Leslie London,Erica Lessem,Grant Theron,Paul D. van Helden,Stefan Niemann,Matthias Merker,David W. Dowdy,Annelies Van Rie,Annelies Van Rie,Gilman Kit Hang Siu,Jotam G. Pasipanodya,Camilla Rodrigues,Taane G. Clark,F. A. Sirgel,Aliasgar Esmail,Hsien-Ho Lin,Sachin R Atre,H. Simon Schaaf,Kwok Chiu Chang,Christoph Lange,Payam Nahid,Zarir F Udwadia,C. Robert Horsburgh,Gavin J. Churchyard,Gavin J. Churchyard,Dick Menzies,Anneke C. Hesseling,Eric L. Nuermberger,Helen McIlleron,Kevin P. Fennelly,Eric Goemaere,Ernesto Jaramillo,Marcus Low,Carolina Morán Jara,Nesri Padayatchi,Robin M. Warren +43 more
TL;DR: Several lines of evidence suggest that alternative mechanisms-including pharmacokinetic variability, induction of efflux pumps that transport the drug out of cells, and suboptimal drug penetration into tuberculosis lesions-are likely crucial to the pathogenesis of drug-resistant tuberculosis.
Journal ArticleDOI
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Haileyesus Getahun,Alberto Matteelli,Ibrahim Abubakar,Mohamed Abdel Aziz,Annabel Baddeley,Draurio Barreira,Saskia Den Boon,Susana Marta Borroto Gutierrez,Judith Bruchfeld,Erlina Burhan,Solange Cavalcante,Rolando Cedillos,Richard E. Chaisson,Cynthia B.E. Chee,Lucy Chesire,Elizabeth L. Corbett,Masoud Dara,Justin T Denholm,Gerard De Vries,Dennis Falzon,Nathan Ford,Margaret Gale-Rowe,Chris Gilpin,Enrico Girardi,Un Yeong Go,Darshini Govindasamy,Alison D. Grant,Malgorzata Grzemska,Ross J Harris,C. Robert Horsburgh,Asker Ismayilov,Ernesto Jaramillo,Sandra V. Kik,Katharina Kranzer,Christian Lienhardt,Philip A. LoBue,Knut Lönnroth,Guy B. Marks,Dick Menzies,Giovanni Battista Migliori,Davide Mosca,Ya Diul Mukadi,Alwyn Mwinga,Lisa J. Nelson,Nobuyuki Nishikiori,Anouk M. Oordt-Speets,Molebogeng Xheedha Rangaka,Andreas Reis,Lisa D. Rotz,Andreas Sandgren,Monica Sañé Schepisi,Holger J. Schünemann,Surender Kumar Sharma,Giovanni Sotgiu,Helen R. Stagg,Timothy R. Sterling,Tamara Tayeb,Mukund Uplekar,Marieke J. van der Werf,Wim Vandevelde,Femke van Kessel,Anna H. van’t Hoog,Jay K. Varma,Natalia Vezhnina,Constantia Voniatis,Marije Vonk Noordegraaf-Schouten,Diana Weil,Karin Weyer,Robert J. Wilkinson,Takashi Yoshiyama,Jean-Pierre Zellweger,Mario C. Raviglione +71 more
TL;DR: The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation and patients with silicosis.
Journal ArticleDOI
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial
Debra Benator,Mondira Bhattacharya,Lorna Bozeman,William J. Burman,Antonino Catanzaro,Richard E. Chaisson,Fred M. Gordin,C. Robert Horsburgh,James Horton,Awal Khan,Christopher J. Lahart,Beverly Metchock,Constance Pachucki,Llewellyn Stanton,Andrew Vernon,M. Elsa Villarino,Cheng Wang Yong,Marc H Weiner,Stephen E. Weis +18 more
TL;DR: Rifapentine once a week is safe and effective for treatment of pulmonary tuberculosis in HIV-negative people without cavitation on chest radiography and clinical, radiographic, and microbiological data help identify patients with tuberculosis who are at increased risk of failure or relapse when treated with either regimen.